Sakanishi Yoshihito, Usui-Ouchi Ayumi, Tamaki Kazunori, Mashimo Keitaro, Ito Rei, Ebihara Nobuyuki
Department of Ophthalmology, Juntendo University Urayasu Hospital, Urayasu City, Chiba, Japan.
Clin Ophthalmol. 2017 May 3;11:829-834. doi: 10.2147/OPTH.S133594. eCollection 2017.
The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO).
Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group. Patient outcomes were examined at 1 week and 1 month postinjection.
Both groups comprised 27 eyes from 27 patients. There was a significant decrease in central macular thickness (CMT) at 1 week and 1 month postinjection in both groups. There was also a significant improvement in best-corrected visual acuity (BCVA) at 1 week and 1 month postinjection in the treatment-naïve group and 1 month in the switching group. Younger age was associated with a good BCVA at 1 month postinjection in the switching group, and the absence of epiretinal membrane was associated with a reduction in CMT at 1 month postinjection in the switching group.
IVA is temporarily effective for treating ME due to BRVO regardless of a history of IVR use.
本研究旨在确定接受玻璃体内注射阿柏西普（IVA）联合或不联合玻璃体内注射雷珠单抗（IVR）治疗视网膜分支静脉阻塞（BRVO）所致黄斑水肿（ME）患者的短期疗效。
患者接受IVA治疗BRVO所致的ME。最初接受IVA治疗的患者被定义为初治组，ME复发后从IVR转换为IVA的患者被定义为转换组。在注射后1周和1个月检查患者的疗效。
两组均包含来自27例患者的27只眼。两组在注射后1周和1个月时中心黄斑厚度（CMT）均显著降低。初治组在注射后1周和1个月时最佳矫正视力（BCVA）显著改善，转换组在注射后1个月时BCVA显著改善。在转换组中，年龄较小与注射后1个月时较好的BCVA相关，无视网膜前膜与转换组注射后1个月时CMT降低相关。
无论有无IVR使用史，IVA对治疗BRVO所致的ME均有短期疗效。
